Top Markets
Coin of the day
CNS Pharmaceuticals, Inc. CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc.

CNSP
株式のランク #33273
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily... CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
株価
$5.47
最終同期: 2026-08-14
時価総額
$7.99M
変化(1日)
6.21%
変化(1年)
7.47%
US
取引 CNS Pharmaceuticals, Inc. (CNSP)

カテゴリー

CNS Pharmaceuticals, Inc.(CNSP)の発行済株式数
August 2026 時点の発行済株式数 0
CNS Pharmaceuticals, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 0 です。August 2026 の終わりには、同社は 0 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
CNS Pharmaceuticals, Inc.(CNSP)の発行済株式数の履歴(2026 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
提供された日付のデータは十分ではありません。
類似企業や競合他社の発行済株式数
企業 発行済株式数
253.90M -
US
62.19M -
NL
- -
CH
- -
KR
0.00 -
BE